4Q EARNINGS: J&J damps 2014 expectations as drug sales impress
This article was originally published in Scrip
Johnson & Johnson’s drug business ended the year on a strong note, posting 12% sales growth in the fourth quarter, but company executives warned not to expect such a robust performance in 2014.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.